Navigation Links
Cytopia Commences Phase II Cancer Drug Study
Date:12/17/2007

Cytopia's first Phase II clinical trial

MELBOURNE, Australia, Dec. 18 /PRNewswire/ -- Cytopia Limited (ASX: CYT) has obtained regulatory approval to proceed with a Phase II clinical study assessing its lead anti-cancer drug in up to 24 multiple myeloma patients. Patient enrolment will soon commence.

This Phase II study is the first in a number of further clinical studies planned for the anti-cancer vascular-disrupting agent CYT997 and will be conducted at the Alfred Hospital in Melbourne, Australia. It will investigate the activity of CYT997 in patients with relapsed or refractory multiple myeloma.

Multiple myeloma is an incurable cancer of plasma cells of the bone marrow, where the cells divide in an uncontrolled manner invading not only the marrow but the solid bone tissue. The human clinical trial follows promising laboratory studies which indicate that CYT997 potently disrupts myeloma cells, including those collected from patients with the disease.

While some significant advances in myeloma therapy have occurred in recent years, disease recurrence almost always occurs with increasing drug resistance leading to uncontrollable and fatal disease.

To be eligible for the study, patients must have failed at least one previous line of approved therapy. The trial is a single-arm, two-stage design with an interim analysis after 14 patients and maximum enrolment of 24 subjects. The company anticipates releasing interim data for this study in the third quarter of 2008.

"We are keen to unlock the potential of CYT997 as a next-generation cancer drug, particularly in indications with unmet medical need," said Mr Andrew Macdonald, CEO of Cytopia. "This study is the first of Cytopia's planned suite of Phase II studies for CYT997 and is a substantial value-adding milestone for the company."

The market for multiple myeloma drugs was estimated at US$930 million in 2006 and is expected to grow to approximately US
'/>"/>

SOURCE Cytopia Limited
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Exelixis Commences Public Offering of Common Stock
3. Milestone Scientific Commences Declaratory Judgment Action With Respect to Its Single Tooth Anesthesia (STA(TM)) System and Compudent(TM) System
4. American Physicians Capital, Inc. Completes $15 Million Authorization and Commences $20 Million Authorization Under Stock Repurchase Program
5. Amarin Commences First Clinical Trial in Cardiovascular ProgramAmarin Commences First Clinical Trial in Cardiovascular Program
6. Ovation further advances development pipeline with new phase III epilepsy study
7. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
8. Mannatech Launches Phase One of New Sales and Training Tools
9. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
10. Manic phase of bipolar disorder benefits from breast cancer medication
11. ARIZONA METH PROJECT Unveils Arizonas Anti-Meth Youth Pledge and Kicks Off Phase Two of Public Awareness Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... (PRWEB) December 26, 2014 ... BambooFlooringChina.com combines beauty, strength and durability. Today, the ... promotion, which is valid until Jan. 30, 2015. ... grain of traditional hardwood. BambooFlooringChina.com is a well-known ... help consumers worldwide to find a reliable bamboo ...
(Date:12/25/2014)... 26, 2014 The report “TS-1 (Colorectal ... on the current treatment landscape, unmet needs, current pipeline ... is an anti-cancer drug which is typically used for ... also used for treating gastric cancer and pancreatic cancer. ... The drug was first approved in 1999 in Japan ...
(Date:12/25/2014)... “Every three months the trends for evening dresses ... will be one of the hottest styles in the next ... the company releases 26 A-line sweetheart evening dresses, and announces ... , “We are trying our best to help a lady ... Along with affordable prices, we provide discounted delivery costs to ...
(Date:12/25/2014)... December 26, 2014 Recently, Dylan Queen, ... has excitedly released its collection of discounted prom dresses, ... Percy, a senior spokesman of the company, the promotion ... this promotion is to expand the UK market. , ... several different colors, lengths, and styles: A-line strapless, empire ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Recently, ... discounts on all its wedding dresses. BellasDress has chosen ... more for gift choices for the holiday season. ... can pick suitable wedding gowns here at discount prices. ... shopping experience at its website. , “All ...
Breaking Medicine News(10 mins):Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2
... , NEW YORK, Aug. 3 Sports ... 24 (th) Annual Great Sports Legends Dinner ... Hotel in the famed Grand Ballroom. Bob Costas will ... Paralysis, a nonprofit organization that serves as the fundraising arm of The ...
... , BOCA RATON, Fla., Aug. 3 MadZone ... international PR firm, TransMedia Group, to publicize its wackiest of all ... while eating ( www.knifeandforklift.com ). ... the Knife and Forklift sets are a sleek combo of utensils ...
... ABU DHABI, UAE, August 3 The region,s first and ... from 22nd -,25th November 2009 at the Hilton Hotel in ... with global military medical leaders and,experts from the British Army, ... Swedish Armed Forces Centre for,Defence Medicine, NATO Centre of Excellence ...
... 3, 2009 The new anti-wrinkle facial filler Dysport, which ... frown lines between the eyes, according to users and independent ... Medical Center. "Our study confirmed that Dysport (abobotulinumtoxinA) is ... Rod Rohrich, chairman of plastic surgery at UT Southwestern and ...
... , EAST BRUNSWICK, N.J., Aug. 2 ... the Company has received a complete response letter from the U.S. ... at this time approve the Company,s Biologics License Application (BLA) for ... to conventional therapy. , , The complete ...
... West African woman,s infection suggests the virus continues to change ... time, researchers have found evidence that the AIDS virus traveled ... to evolve even as scientists race to vanquish it. , ... African country of Cameroon carried a strain of the AIDS ...
Cached Medicine News:Health News:Sports Icons Troy Aikman, Clyde Drexler, Mike Piazza, Ivan Lendl and Dara Torres are Among the Elite Named 2009 'Great Sports Legends' 2Health News:Sports Icons Troy Aikman, Clyde Drexler, Mike Piazza, Ivan Lendl and Dara Torres are Among the Elite Named 2009 'Great Sports Legends' 3Health News:Sports Icons Troy Aikman, Clyde Drexler, Mike Piazza, Ivan Lendl and Dara Torres are Among the Elite Named 2009 'Great Sports Legends' 4Health News:Madzone Marketing LLC Taps TransMedia Group to Provide Publicity Lift to Knife and Forklift(TM) 2Health News:Brand New Conference on Developing 21st Century Military Medical Capabilities to be Held in Abu Dhabi 2Health News:Dysport proves safe, effective anti-wrinkle treatment, UT Southwestern plastic surgeons find 2Health News:Savient Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for KRYSTEXXA(TM) 2Health News:Savient Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for KRYSTEXXA(TM) 3Health News:Savient Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for KRYSTEXXA(TM) 4Health News:Savient Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for KRYSTEXXA(TM) 5Health News:Savient Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for KRYSTEXXA(TM) 6Health News:Scientists ID First Human With Gorilla Strain of HIV 2
(Date:12/22/2014)... DUBLIN , Dec. 22, 2014 Research and ... addition of the "US Self-monitoring Blood Glucose Market" ... http://photos.prnewswire.com/prnh/20130307/600769 This market insight focuses ... in the United States . Reimbursement ... studied. Thorough product analyses for more than 73 SMBG ...
(Date:12/22/2014)... 2014  ConvaTec, a privately-held medical products and technologies ... Interim Chief Executive Officer of the company, effective December ... Berger .  "The Board of Directors of ConvaTec thanks ... the past three years," said Magnus Lundberg , ... confident that the company is well positioned for the ...
(Date:12/22/2014)... Mass , Dec. 22, 2014 /PRNewswire/ -- RXi ... biotechnology company focused on discovering, developing and commercializing ... RNA-targeted technologies, today issued the following open letter ... Cauwenbergh , Dr. Med. Sc. Dear ... days a number of inaccurate statements posted on ...
Breaking Medicine Technology:US Self-monitoring Blood Glucose Market 2ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6
... (NYSE: DHR ) announced that Executive Vice President ... at the Goldman Sachs Global Industrials Conference in New York, ... The company also announced that President and Chief Executive Officer, ... W. Baird Industrial Conference in Chicago, Illinois on Tuesday, November ...
... (Nasdaq: ITMN ) today announced results from ... September 30, 2010.  InterMune also highlighted its recent clinical ... financial guidance for 2010.   Dan Welch, ... "Earlier this month we announced the sale of our ...
Cached Medicine Technology:InterMune Reports Third Quarter 2010 Financial Results 2InterMune Reports Third Quarter 2010 Financial Results 3InterMune Reports Third Quarter 2010 Financial Results 4InterMune Reports Third Quarter 2010 Financial Results 5InterMune Reports Third Quarter 2010 Financial Results 6InterMune Reports Third Quarter 2010 Financial Results 7InterMune Reports Third Quarter 2010 Financial Results 8
Stainless steel lancet blade in stainless steel....
In Stainless steel. Available in 1.5, 2.0,3.0 & 3.5 MM...
AXIOM Multistar is a ceiling-mounted single plane C-Arm system for universal angiography, diagnostics and intervention...
... The Allura Xper FD10 supports the cardiac ... that allows personalization of personalized user settings. ... tableside in one intuitive user interface. For ... and StentBoost can be controlled from tableside.,The ...
Medicine Products: